Abstract. Colorectal cancer (CRC) has been one of the most common types of cancer for decades worldwide. The pathogenesis of CRC is associated with the processes of activating oncogenes and inactivating anti-oncogenes. Platelet-derived growth factor-D (PDGF-D) was confirmed to regulate migration, invasion, proliferation, apoptosis and metastasis in various cancer cells. Overexpression of PDGF-D exists in a number of human malignancies, including pancreatic, prostate and breast cancer. However, the expression and function of PDGF-D and its associated molecular mechanism in CRC remain unclear. Thus, the expression of PDGF-D was detected in CRC tissues and human colon cancer lines. Subsequently, the effects of PDGF-D on the invasion, migration and proliferation of cancer cells were investigated. The corresponding molecular mechanism had also been explored. The present study revealed that PDGF-D was upregulated not only in CRC tissues but also in CRC cell lines, and simultaneously, facilitated the processes of migration, invasion and proliferation. Silencing PDGF-D in the SW480 cell line inhibited migration, invasion and proliferation distinctly, with reduced expression of Notch1 and matrix metalloproteinase-9. Furthermore, upregulating PDGF-D in HCT116 cells led to the opposite results. These findings indicate that PDGF-D may be developed into a potential therapeutic target for CRC treatment.
Introduction
Colorectal cancer (CRC) is one of the most common types of malignancy in Western countries, and is the cause of a high number of cancer-associated mortalities every year (1) . In the past decades, the prevalence of CRC in China has increased rapidly, which may be associated with westernized lifestyle, longer lifespan and a poor CRC screening system (2, 3) . Previous studies have shown that the process of CRC formation refers to a gradual activation of oncogenes and inactivation of anti-oncogenes (4) . However, the mechanisms of CRC tumorigenesis and tumor progression are still not illustrated clearly. Consequently, identifying more credible biomarkers may help with CRC prognosis estimation and provide novel potential targets for therapy.
Platelet-derived growth factor (PDGF)-D belongs to the PDGF family, whose members are known as a mesenchymal growth factors that promote epithelial-stromal communication (5) . Platelet-derived growth factor-D (PDGF-D) exerts its biological functions by specifically binding to its cognate receptor, platelet-derived growth factor receptor-β (PDGFR-β), leading to rapid phosphorylation of PDGFR-β and consequent activation of numerous downstream signaling pathways (6) . Previous studies have shown that PDGF-D is involved in carcinogenesis, particularly regulating the course of epithelial-to-mesenchymal transition, which facilitates tumor proliferation and metastasis (7) (8) (9) . Furthermore, PDGF-D has been reported to be associated with the mechanistic target of rapamycin (mTOR), Notch, nuclear factor-κB (NF-κB), B-cell lymphoma-2 (Bcl-2) and CXC motif chemokine receptor 4 (CXCR4) signaling pathways (10) . Overexpression of PDGF-D was also observed in various human tumors, including pancreatic, prostate, gastric and breast cancer, predicting that PDGF-D is involved in cancer development and progression (7-9,11).
As there is little clear evidence about the expression and function of PDGF-D in CRC thus far, it will be necessary to explore the significant role of PDGF-D in CRC. In the present study, PDGF-D messenger RNA (mRNA) level and protein expression were examined in CRC tissues, paired normal tissues and cell lines. The effects of PDGF-D on CRC behaviors, including migration, invasion and proliferation, were then surveyed. By upregulating and downregulating the expression level of PDGF-D in colon cell lines, the detailed functions of PDGF-D were studied, with the aim of clarifying its potential mechanism. 25-87 years) . All samples were obtained with written informed consent from the patients. Part of these specimens were immersed in 5% paraformaldehyde solution at 4˚C for immunohistochemistry (IHC), and the remaining were immediately frozen and stored at -80˚C.
Materials and methods

Ethics
IHC. CRC specimens were fixed in 5% paraformaldehyde solution, as described previously (12) . For calculating the protein level of PDGF-D, the general procedure was designed as follows: i) Record the intensity of dyeing in stained tissues (negative, 0; weak positive, 1; moderate positive, 2; and strong positive, 3); ii) calculate the quantity of stained cancer cells (0, <10%; 1, <25%; 2, <50%; and 3, ≥50%); iii) multiply the two indexes to calculate the staining index (SI); and iv) the final expression is considered negative when SI <3 and positive when SI ≥4.
Cell culture and lentivirus transfection. Human colon cancer SW480 and SW620 cells were cultured in L15 (HyClone; GE Healthcare Life Sciences, Little Chalfont, UK), HCT116 cells were cultured in McCoy's 5A (HyClone; GE Healthcare Life Sciences), DLD-1 cells were cultured in RPMI-1640 (Wuhan Goodbio Technology, Wuhan, China) and LoVo cells were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) complete medium with 10% fetal bovine serum (ScienCell Research Laboratories, Inc., Carlsbad, CA, USA), and were grown in 25-cm 2 polystyrene tissue culture flasks (Corning Incorporated, Corning, NY, USA) at 37˚C in an atmosphere containing 5% CO 2 for between 48 and 72 h. Lentivirus transfection was used to up-and downregulate the PDGF-D expression in cell lines. The specific procedure has been described previously (13) . The short hairpin (sh)PDGF-D-lentivirus and complementary DNA (cDNA)-PDGF-D-lentivirus were purchased from Shanghai GeneChem., Shanghai, China.
Detection of apoptosis by flow cytometry. Subsequent to successful transfection, the SW480 and HCT116 cells were collected to conduct detection of apoptosis by flow cytometry, and the specific operation steps have been presented in a previous study (14) . The Annexin V/propidium iodide apoptosis detection kit was used according to the manufacturer's protocol (Wuhan Antgene Biotechnology, Wuhan, China).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
The detailed procedures and notes of RT-qPCR were reported in a previous study (15) . In brief, TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract total RNA from cells, CRC tissues and paired normal controls. Subsequently, the RT of total RNAs was performed with PrimeScript RT Master mix (Takara Bio, Inc., Otsu, Japan). Finally, the expected nucleic acid amplification products were detected in the StepOnePlusÔ Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with SYBR-Green Master mix (Takara Bio, Inc.). mRNA quantity of each gene was calculated using the 2 -ΔΔCq method (16) and normalized to GAPDH. The primer sequences of PDGF-D (forward, GTG GAG GAA ATT GTG GCT GT and reverse, CGT TCA TGG TGA TCC AACTG), and the internal control (GAPDH forward, GGG GAG CCA AAA GGG TCA TCA TCT and reverse, GAC GCC TGC TTC ACC ACC TTC TTG) were designed according to a previous study (17) .
Western blot analysis. The specimens and cells were lysed in an appropriate amount (100 µl) of lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) with phenylmethylsulfonyl fluoride for total protein extraction. The protein concentration in the lysates was then detected by bicinchoninic acid assay. Equal quantities of total protein (10 µl/lane) were loaded onto SDS-PAGE (12% gel) and then separated by electrophoresis. The separated proteins were transferred to a polyvinylidene fluoride membrane, which was subsequently blocked with 5% skimmed milk and TBS-Tween-20 for 1 h at room temperature. The membranes were then incubated with primary antibodies at 4˚C overnight. The primary antibodies used in the study were as follows: Anti-PDGF-D (cat. no. ab181845; dilution, 1:500; Abcam, Cambridge, MA, USA), anti-PDGFR-β (cat. no. Esap11645; dilution, 1:500; Wuhan Elabscience Biotechnology, Wuhan, China), anti-Notch1 (cat. no. SC-6014; dilution, 1:500; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and anti-MMP-9 (cat. no. ab58803; dilution, 1:500; Abcam). Subsequently, either the horseradish peroxidase (HRP-) labeled goat anti-rabbit immunoglobulin G (cat. no. GB23303; dilution, 1:1,000; Wuhan Goodbio Technology) or the HRP-labeled goat anti-mouse IgG (cat. no. GB23301; dilution, 1:1,000; Wuhan Goodbio Technology) secondary antibody was applied to the membrane for 1 h at room temperature. An enhanced chemiluminescence system (cat. no. G2014; Wuhan Goodbio Technology) and Image J software (version 2; National Institutes of Health, Bethesda, MD, USA) were used to analyze the protein expression.
Transwell migration and Matrigel invasion assays. Cell
Transwell assays were performed to test the invasion and migration of cancer cells. The specific procedure was previously reported (18) . In the present study, Transwell chambers (24-well, 8-µm pore membranes) were purchased from Corning Incorporated. Matrigel (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was used in cell invasion analysis, but not in the migration assay.
Cell proliferation assays. A Cell Counting kit (CCK)-8 assay (Beyotime Institute of Biotechnology) was used to detect cell proliferation. Following inoculation onto a 96-well plate, cells were cultured in an incubator for 24 h at 37˚C in an atmosphere containing 5% CO 2 . An appropriate amount (10 µl) of CCK-8 solution was then added to each well, and subsequently, the cells were kept in the incubator for 1-4 h. Eventually, cell proliferation was analyzed by measuring the absorbance at 450 nm with a microplate reader (Thermo Fisher Scientific, Inc.).
Statistical analysis.
All experiments were performed at least three times independently. All results shown in our study were analyzed using SPSS statistical software (version 22.0; IBM Corp., Armonk, NY, USA). The results are expressed as the mean ± standard deviation. Statistical analyses were performed using Student's t and χ 2 tests. P<0.05 was considered to indicate a statistically significant difference.
Results
PDGF-D is highly expressed in CRC tissues
. PDGF-D protein expression was investigated through IHC detection, which revealed that PDGF-D was highly expressed in CRC tissues (Fig. 1A and B) . In total, 53.3% (24/45) of CRC tissues were positive for PDGF-D protein expression in the cytoplasm, while 11.1% (5/45) of the paired normal colorectal tissues were positive for PDGF-D protein expression (P<0.0001; Fig. 1C ). Subsequently, the mRNA level of PDGF-D was detected in CRC tissues and paired normal colorectal tissues by qPCR analysis. The results demonstrated that PDGF-D mRNA expression was averagely 4.6-fold higher in CRC tissues than in normal tissues (P<0.05; Fig. 1D ). Fig. 2A and B) . The corresponding mRNA levels were detected by qPCR and the results were similar to the expression of PDGF-D protein (Fig. 2C) . Furthermore, the expression of PDGFR-β in SW480 and HCT116 cell lines was detected by qPCR and western blot analysis. The results demonstrated that PDGFR-β was highly expressed in SW480 cells and expressed at a lower level in HCT116 cells (Fig. 2) .
PDGF-D and PDGFR
Knockdown of PDGF-D in SW480 cells decreases the migration, invasion and proliferation capacity of cancer cells by downregulation of Notch1 and MMP-9.
Knockdown of PDGF-D in the SW480 cell line was successfully established by lentiviral transfection (Fig. 3A) . The capacity of migration, invasion and proliferation of SW480 cells was significantly decreased compared with that of the control (Fig. 3B-D) . In order to study the potential mechanism, the associated signaling pathways reported previously, including mTOR, Notch, NF-κB, Bcl-2 and CXCR4, were screened by western blot analysis (10) . The expression of Notch1 and MMP-9 was observed to decline following knockdown of PDGF-D in SW480 cells (Fig. 3A) . Furthermore, the apoptotic rate of transfected SW480 cells was determined. No clear difference was observed between the shPDGF-D-lentivirus-transfected group and the negative control group ( Fig. 3E and F ; negative control vs. shPDGF-D-lentivirus=6.5 vs. 6.8%). cell line was successfully established by lentiviral transfection (Fig. 4A) . Compared with that of the control HCT116 cells, the capacity of migration, invasion and proliferation of PDGF-D upregulated HCT116 cells were identified to be markedly increased (Fig. 4B-D) . Our previous study results revealed that Notch1 and MMP-9 are associated with the migration, invasion and proliferation ability of colon cancer cells; thus, the expression of Notch1 and MMP-9 was detected in the PDGF-D-upregulated HTC116 cells. Notably, a significantly increased level of Notch1 and MMP-9 expression was observed in the PDGF-D-upregulated cells (Fig. 4A) . Furthermore, the apoptotic rate of transfected HCT116 cells was detected. The results revealed that there was no clear difference between the cDNA-PDGF-D-lentivirus-transfected group and the negative control group ( Fig. 4E and F; negative  control vs. cDNA-PDGF-D-lentivirus=9.1 vs. 8.6% ). 
Upregulation of PDGF-D expression in HCT116 cells enhances the capacity of migration, invasion and proliferation of cancer cells by increasing Notch1 and MMP-9 levels. Upregulation of PDGF-D expression in the HCT116
Discussion
CRC is the one of the most common types of malignancy around the world, with >1.35 million novel cancer cases and ~690,000 cancer-associated mortalities in 2012 (19) . It has been widely accepted that tumorigenesis and tumor progression of CRC are associated with multiple epigenetic changes and molecular alterations (20, 21) . Identifying more novel biomarkers and their corresponding molecular mechanism of carcinogenesis facilitates the development of new approaches for the prevention and treatment of CRC (22) .
Several previous studies indicated that the expression of PDGF-D is upregulated in various malignancies, including prostate, breast, pancreatic and gastric cancer (7) (8) (9) 11) . Furthermore, PDGF-D has been shown to be a critical factor that regulates the processes of cell proliferation, apoptosis, migration, invasion, angiogenesis and metastasis (23) . As there were few studies concerning the function and mechanism of PDGF-D in CRC tumorigenesis and progression, the present study was performed.
According to the present study, 53.3% (24/45) of CRC tissues exhibited overexpression of PDGF-D protein by immunohistochemical detection, and similarly, the majority of the CRC tissues exhibited overexpression of PDGF-D mRNA by qPCR assay, with a significant difference (P<0.05). These results revealed that PDGF-D is one of the biomarkers that promotes the process of CRC oncogenesis, similar to other types of cancer reported previously (24, 25) .
In order to unravel the potential mechanism, subsequent experiments were conducted in vitro. Human colon cell lines, including SW480, SW620, HCT116, CT26, DLD-1 and LoVo, were screened for the expression of PDGF-D (data of SW620, DLD-1 and LoVo cells are not shown). Finally, SW480 was selected for its overexpression of PDGF-D, and HCT116 was selected for its low expression of PDGF-D. In the two cell lines, the expression of PDGFR-β exhibited similar changes, predicting that PDGF-D exerts its cellular functions through PDGFR-β. PDGF-D expression was then successfully downregulated in SW480 cells and upregulated in HCT116 cells. For the purpose of excluding the possibility that the following experiments were affected by different apoptosis rates subsequent to transfection, detection of apoptosis was conducted by flow cytometry. The results indicated that there was no clear difference between the experimental and negative control groups. As expected, the potential of migration, invasion and proliferation of cancer cells changed accordingly. These results suggest that PDGF-D promotes CRC tumorigenesis and progression by regulating the capacity of migration, invasion and proliferation in CRC.
Accumulating evidence suggests that PDGF-D promotes tumorigenesis and cancer progression by regulating several downstream signaling pathways (26) (27) (28) . In prostate cancer, upregulated PDGF-D promotes cell proliferation and tumor growth through the mTOR signaling pathway (by activating the downstream targets S6 kinase and 4E binding protein) and upregulation of Bcl-2 (26) . In breast cancer, overexpression of PDGF-D improves the aggression of cancer cells by upregulating the Notch, NF-κB and CXCR4 signaling pathways (17, 27) . In pancreatic cancer, overexpressed PDGF-D increases the capacity of proliferation and invasion by activating the Notch and NF-κB signaling pathways (28) . In the present study, it was shown that the expression of Notch1 and MMP-9 markedly decreased when PDGF-D was successfully downregulated in SW480 cells, and by contrast, the expression of Notch1 and MMP-9 increased significantly in HCT116 cells when PDGF-D was effectively upregulated. Since MMP-9 is the known downstream target of the Notch and NF-κB signaling pathways (29, 30) , the results may predict that PDGF-D promotes CRC migration, invasion and proliferation by regulating the Notch and/or NF-κB signaling pathways. Therefore, future studies will provide more evidence about the association between PDGF-D and the Notch and NF-κB signaling pathways, and subsequently elucidate the complete mechanism.
In summary, the overexpression of PDGF-D, existing in the majority of human CRC tissues, promotes CRC migration, invasion and proliferation. In vitro experiments demonstrated that Notch1 and MMP-9 were upregulated by PDGF-D, and the invasiveness of cancer cells was distinctly enhanced as PDGF-D was overexpressed. Thus, the PDGF-D gene may be developed into a novel therapeutic target of human CRC.
